<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890279</url>
  </required_header>
  <id_info>
    <org_study_id>ADPKDhypertension</org_study_id>
    <nct_id>NCT00890279</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)</brief_title>
  <official_title>Phase II Study for the Second-Line Treatment of Hypertension in Patients With Autosomal Dominant Polycystic Kidney Disease; ACEI vs. CCB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Labour and Welfare, Japan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study examines the safety and efficacy of combination therapy for hypertension
      in patients with autosomal dominant polycystic kidney disease (ADPKD). This study examines
      the safety and efficacy of combination therapy by imidapril (ACEI) or cilnidipine (CCB) in
      ADPKD patients whose blood pressure is not controlled under 120/80 mmHg by candesartan (ARB)
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maximum dosage of candesartan is 8 mg/day. Dosage of imidapril is in the range of 2.5-10
      mg/day. Dosage of cilnidipine is in the range of 5-20mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR</measure>
    <time_frame>every 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney Volume measured by MRI</measure>
    <time_frame>every 3 months to every 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine level</measure>
    <time_frame>every 3 months to every 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of hemodialysis, cardiovascular events and central nervous vascular events</measure>
    <time_frame>every 3 months to every 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Kidney, Polycystic, Autosomal Dominant</condition>
  <arm_group>
    <arm_group_label>Cilnidipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imidapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilnidipine</intervention_name>
    <description>Cilnidipine up to 20 mg</description>
    <arm_group_label>Cilnidipine</arm_group_label>
    <other_name>ATELEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imidapril</intervention_name>
    <description>Imidapril up to 10 mg per day</description>
    <arm_group_label>Imidapril</arm_group_label>
    <other_name>TANATRIL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADPKD patients

          -  Blood pressure measured at out-patient setting is above 120/80 mmHg

          -  Age between 20 and 60 years old

          -  eGFR more than 30 ml/min/1.73m2

          -  Patients give informed consent

        Exclusion Criteria:

          -  Patients with severe cardiovascular and hepatic disorders

          -  Patients with complications of central nervous vascular disorders

          -  Women who are breast feeding and females of childbearing potential who are not using
             acceptable contraceptive methods

          -  Patients currently engaging in other experimental protocol

          -  Patients with intracranial aneurysma

          -  Patients who must use diuretics

          -  Allergic patients to Candesartan or Cilnidipine

          -  Patients whose hypertension is not controlled by medication of this protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeo Horie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Teikyo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shigeo Horie, MD</last_name>
    <phone>+81339642497</phone>
    <email>shorie@med.teikyo-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Satoru Muto, MD, PhD</last_name>
    <phone>+81339642497</phone>
    <email>muto@med.teikyo-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Medicine II, Hokkaido Univserity School of Medicine</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0608638</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshio Mochizuki, MD</last_name>
      <phone>+81117065915</phone>
      <email>mtoshi@med.hokudai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Toshio Mochizuki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital Kajigaya, Kidney center</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>2138587</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshihumi Ubara, MD</last_name>
      <phone>+81448775111</phone>
      <phone_ext>6064</phone_ext>
      <email>ubara@toranomon.gr.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshihumi Ubara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine II, Nippon Medical School</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1138602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasuhiko Iino, MD</last_name>
      <phone>+81338222131</phone>
      <email>iinoyasuhiko@nms.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yasuhiko Iino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Teikyo University School of Medicine</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>1738605</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigeo Horie, MD</last_name>
      <phone>+81339642497</phone>
      <email>shorie@med.teikyo-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Satoru Muto, MD</last_name>
      <phone>+81339642497</phone>
      <email>muto@med.teikyo-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Shigeo Horie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital, Kidney center</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1058470</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenmei Takaichi, MD</last_name>
      <phone>+81335881111</phone>
      <phone_ext>7065</phone_ext>
      <email>takaichi@toranomon.gr.jp</email>
    </contact>
    <investigator>
      <last_name>Kenmei Takaichi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1058471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Urology, Kyorin University School of Medicine</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>1818611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eiji HIgashihara, MD</last_name>
      <phone>81422475511</phone>
      <email>ehigashi@kyorin-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kikuo Nutahara, MD</last_name>
      <phone>81422475511</phone>
      <email>kinuta@kyorin-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Eiji Higashihara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kikuo Nutahara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Urology, National Hospital Organaization Chiba-East Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>2608712</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Koichi Kamura, MD</last_name>
      <phone>+81432615171</phone>
      <phone_ext>7607</phone_ext>
      <email>kamura@cehpnet.com</email>
    </contact>
    <investigator>
      <last_name>Koichi Kamura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences</name>
      <address>
        <city>Niigata</city>
        <zip>9518510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ichiei Narita, MD</last_name>
      <phone>+813252272193</phone>
      <email>naritai@med.niigata-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Ichiei Narita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>December 1, 2009</last_update_submitted>
  <last_update_submitted_qc>December 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shigeo Horie, M.D./Chairman of the Department of Urology at Teikyo University</name_title>
    <organization>Teikyo University, School of Medicine</organization>
  </responsible_party>
  <keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Angiotensin-II Receptor Blocker</keyword>
  <keyword>Calcium Channel Blocker</keyword>
  <keyword>Angiotensin converting enzyme inhibitor</keyword>
  <keyword>Kidney Volume</keyword>
  <keyword>eGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Imidapril</mesh_term>
    <mesh_term>Cilnidipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

